Drug Profile
Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics
Alternative Names: CHR-3996; Nana-val; Tractinostat; Tractinostat-Viracta-Therapeutics; Valganciclovir/Nanatinostat combination therapy - Viracta Therapeutics; VRx-3996Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Developer Chroma Therapeutics; Viracta Therapeutics
- Class Amides; Antineoplastics; Antivirals; Hypoxanthines; Pyrimidines; Quinolines; Small molecules
- Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphoma
- Phase I/II Multiple myeloma; Nasopharyngeal cancer; Solid tumours
- Phase I Cancer
- No development reported Gastric cancer; Post-transplant lymphoproliferative disorder
Most Recent Events
- 15 Apr 2024 Updated efficacy and adverse events data from the phase II NAVAL-1 trial in Lymphoma released by Viracta Therapeutics
- 08 Mar 2024 Viracta Therapeutics plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO, Tablets) (NCT06302140)
- 01 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO) (NCT06302140)